8-K: NovAccess Global Secures $100,000 Loan to Bolster Working Capital

NovAccess Global Inc. has entered into a securities purchase agreement for a $100,000 loan to support its working capital needs.

Summary

• NovAccess Global Inc. has secured a loan of up to $100,000 from AJB Capital Investments, LLC, through a securities purchase agreement.
• The initial draw was $25,000, with potential for two additional $25,000 draws in March and April 2024.
• The loan has a 20% original issuance discount, meaning NovAccess received $80,000, and carries a 12% annual interest rate.
• The loan is due on August 27, 2024, and must be repaid from proceeds of any loan or capital raise exceeding $5.0 million.
• The loan agreement includes restrictions on asset sales, additional debt issuance, and maintaining the company's stock listing.
• Failure to comply with the loan terms could result in an 18% default interest rate, accelerated due date, and potential conversion of the debt into shares at a discount.
• NovAccess has granted AJB a security interest in all company assets, including the equity of StemVax, LLC.
• NovAccess is required to file a Form S-1 by May 27, 2024, to register the shares issuable upon conversion of the note.

Sentiment

Score: 4

Explanation: The document indicates a necessary but potentially risky financing move. While the loan provides immediate capital, the terms are not particularly favorable, with a high discount and interest rate, and significant restrictions and default penalties. This suggests a degree of financial strain and a need for future capital raising.

Positives

• The loan provides immediate working capital of $25,000, with potential for an additional $50,000.
• The loan can be prepaid at any time without penalty.
• The company has secured funding to support its operations.

Negatives

• The loan has a 20% original issuance discount, reducing the net proceeds to $80,000.
• The 12% interest rate increases the cost of borrowing.
• The loan agreement includes restrictions on asset sales and additional debt issuance.
• A default could trigger an 18% interest rate, accelerated due date, and conversion of the debt into shares at a discount.
• The company has granted a security interest in all company assets, including the equity of StemVax, LLC.

Risks

• Failure to repay the loan or comply with the covenants could lead to significant penalties, including a default interest rate of 18% and potential conversion of the debt into shares at a discount.
• The security interest granted to AJB puts all company assets at risk.
• The restrictions on asset sales and additional debt issuance could limit the company's flexibility.
• The requirement to file a Form S-1 by May 27, 2024, adds a compliance burden.

Future Outlook

The company intends to use the loan proceeds for working capital and general corporate purposes. They are also required to file a Form S-1 to register the shares issuable upon conversion of the note.

Industry Context

This type of financing is common for small companies seeking to raise capital for operations. The terms of the loan, including the discount and interest rate, reflect the risk associated with lending to a company of this size and stage.

Comparison to Industry Standards

• The 20% original issuance discount is relatively high, suggesting a higher risk profile for NovAccess compared to more established companies.
• The 12% interest rate is also on the higher end, reflecting the risk associated with lending to a smaller, less established company.
• The requirement to repay the loan from proceeds of a capital raise exceeding $5 million is a common clause in such agreements, indicating the lender's expectation of future growth and capital raising activities.
• The security interest granted to AJB is a standard practice in secured lending, providing the lender with recourse in case of default.
• The requirement to file a Form S-1 is a standard procedure for companies seeking to register shares for public resale.

Stakeholder Impact

• Shareholders face potential dilution if the note is converted into shares.
• Employees may be impacted by the company's financial situation and any potential restructuring.
• Creditors may be concerned about the company's ability to repay its debts.
• Customers and suppliers may be affected by any changes in the company's operations.

Next Steps

• NovAccess will draw down the remaining $50,000 of the loan in March and April.
• NovAccess will file a Form S-1 by May 27, 2024, to register the shares issuable upon conversion of the note.
• NovAccess will need to manage its finances carefully to avoid defaulting on the loan.
• NovAccess will need to seek additional funding or generate sufficient revenue to repay the loan by August 27, 2024.

Key Dates

Keywords

loan, securities purchase agreement, promissory note, working capital, AJB Capital Investments, debt financing, security agreement, registration rights, Form S-1, conversion